CFZ533B
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $90,332 | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $90,332 | 6 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 48-WEEK, 6-ARM, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED MULTICENTER TRIAL TO ASSESS THE SAFETY AND EFFICACY OF MULTIPLE CFZ533 DOSES ADMINISTERED SUBCUTANEOUSLY IN TWO DISTINCT POPULATIONS OF PATIENTS WITH SJ??GREN???S SYNDROME (TWINSS) | Novartis Pharmaceuticals Corporation | $90,332 | 0 |
Top Doctors Receiving Payments for CFZ533B
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Madison, WI | $90,332 | 6 |
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $90,332
- Total Doctors 0
- Transactions 6
About CFZ533B
CFZ533B is a biological associated with $90,332 in payments to 0 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $90,332 was paid across 6 transactions to 0 doctors.
The most common payment nature for CFZ533B is "Unspecified" ($90,332, 100.0% of total).
CFZ533B is associated with 1 research study, including "A 48-WEEK, 6-ARM, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED MULTICENTER TRIAL TO ASSESS THE SAFETY AND EFFICACY OF MULTIPLE CFZ533 DOSES ADMINISTERED SUBCUTANEOUSLY IN TWO DISTINCT POPULATIONS OF PATIENTS WITH SJ??GREN???S SYNDROME (TWINSS)" ($90,332).